Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab-论文-万方医学网

首页> > Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab

Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab

导出原文传递

翻译打印收藏纠错

作者： Altieri, Manuela ^[1] ; Capuano, Rocco ^[2] ; Conte, Miriana ^[3] ; Donnarumma, Giovanna ; Grimaldi, Elena ; Coppola, Nicola ; Galdiero, Massimiliano ; D'Ambrosio, Alessandro ; Tedeschi, Gioacchino ; Gallo, Antonio

作者单位： Dept Adv Med & Surg Sci DAMSS,Univ Campania Luigi Vanvitelli ^[1] Dept Expt Med,Univ Campania Luigi Vanvitelli ^[2] Dept Mental Hlth & Publ Med,Univ Campania Luigi Vanvitelli ^[3]

关键词 COVID-19 Humoral response Multiple sclerosis Natalizumab BNT162b2 mRNA COVID-19 vaccine Vaccine

发布时间 2022-06-23

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab

相似文献

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab

相似文献

相关期刊

检索历史清除